Notably, SFPQ dysregulation has been reported in ovarian, breast, and prostate cancers, that also harbor recurrent mutations or altered expression of RAD51 family members, suggesting that disruption of this SFPQ–RAD51 axis may represent a shared vulnerability across these malignancies [16,20,54–57]. This evidence concerns the gene RAD51 and prostate carcinoma.